Suchergebnisse - "Bearz, Alessandra"

PubPharm (176)

1

CONTACT-01 : A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Neal, J. | Pavlakis, N. | Kim, S. | +19

2

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors : A Systematic Review and Meta-Analysis

enthalten in: JAMA network open | 2024

von Maiorano, B. | Di Maio, M. | Cerbone, L. | +104

3

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer : Interim Results of the MAURIS Phase IIIb Trial

enthalten in: The oncologist | 2024

von Bria, E. | Morgillo, F. | Garassino, M. | +18

4

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical pharmacokinetics | 2024

von Chen, J. | Bearz, A. | Kim, D. | +14

5

Case report : First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

enthalten in: Frontiers in oncology | 2024

von De Carlo, E. | Bertoli, E. | Schiappacassi, M. | +5

6

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Drilon, A. | Camidge, D. | Lin, J. | +131

7

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical pharmacokinetics | 2023

von Chen, J. | Bearz, A. | Kim, D. | +14

8

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

enthalten in: The New England journal of medicine | 2023

von Loriot, Y. | Matsubara, N. | Park, S. | +116

9

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer : An Italian Expert Panel Discussion

enthalten in: Current oncology (Toronto, Ont.) | 2023

von Gridelli, C. | Tiseo, M. | Cortinovis, D. | +6

10

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Bearz, A. | Martini, J. | Jassem, J. | +12

CommentIn: J Thorac Oncol. 2023 Nov;18(11):1434-1442. - PMID 37879764

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]